Laurion Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Laurion Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-19,536	Closed	-$1.53M	–	1057
2019 Q1	$1.53M	Buy	+19,536	New	+$1.48M	0.02%	444
2018 Q2	–	Sell	-3,206	Closed	-$330K	–	1459
2018 Q1	$330K	Buy	+3,206	New	+$317K	﹤0.01%	1113

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Laurion Capital Management's LGND Position: Q2 2019 in Review

Laurion Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 19,536 shares — an estimated $1.53M sold.

Laurion Capital Management first reported a position in LGND in Q1 2018 and held it in 2 quarters. The position peaked at $1.53M in Q1 2019. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

Laurion Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Laurion Capital Management sold 19,536 Ligand Pharmaceuticals shares in Q2 2019, an estimated $1.53M.
Laurion Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 2 quarters.
Laurion Capital Management's Ligand Pharmaceuticals position peaked at $1.53M in Q1 2019.
305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Laurion Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.